MD Anderson and Affimed announce clinical immuno-oncology...
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering...
Connect to End Cancer launches at South By Southwest 2017...
HOUSTON ― The University of Texas MD Anderson Cancer Center, in collaboration with the AT&T Foundry for Connected Health, will...
Mulva Family Foundation Contributes $75 Million to Fund...
James and Miriam Mulva and the Mulva Family Foundation have donated $50 million to advance neuroscience at The University of Texas at...
Older women with breast cancer report better cosmetic satisfaction...
In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The...
Image-guided biopsy identifies patients who achieve...
In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer...
MD Anderson affirms Surgeon General’s conclusions on...
The University of Texas MD Anderson Cancer Center fully supports the United States Surgeon General’s call to action to prevent the use...
Ronald A. DePinho, M.D., on passage of the 21st Century...
With strong bipartisan support, the U.S. House and Senate have passed transformative legislation, the 21st Century Cures Act, which...
Nivolumab with chemotherapy improves response, survival in...
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall...
Research shows patients ineligible for studies may benefit...
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based...
Biomarker may predict which formerly treated cancer...
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes...